Detalhe da pesquisa
1.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Br J Haematol
; 201(5): 845-850, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895158
2.
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
J Clin Oncol
; 41(23): 3945-3955, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315268
3.
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.
Insights Imaging
; 14(1): 170, 2023 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37840055
4.
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma.
BMJ Open
; 12(10): e062504, 2022 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36288835
5.
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.
Blood Cancer J
; 12(4): 52, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35365598
6.
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma.
Insights Imaging
; 13(1): 123, 2022 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35900614
7.
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
BMJ Open
; 11(3): e046225, 2021 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762245